New study seeks people who aren’t regular
A new research study is currently looking for adults aged 18-75 who suffer from severe constipation. Atlantia Clinical Trials are investigating the effects of a food supplement on those with severe constipation - people who experience 1-2 bowel movements per week.
Constipation is very common in the general population around the world with prevalence increasing progressively after 60 years of age. It is usually accompanied by various symptoms such as abdominal discomfort and/or gas depending on how severe it is.
As well as causing long-term problems, chronic constipation disrupts people's daily lives by reducing their energy and enthusiasm. People that suffer from constipation generally need more medical visits which can also be a financial burden.
This study is investigating whether the consumption of this fibre supplement will increase the frequency of bowel movements. This soluble fibre is digested and fermented by gut bacteria and is believed to contribute to a healthy gut, increasing stool frequency as well as improving stool consistency. Recent studies show this supplement has prebiotic effects, which means it helps to promote the growth of beneficial microbes in the gut and decreasing the bad bacteria, which may also help people suffering from constipation.
There is a need for effective non-medical treatments for the broad population that suffer with constipation symptoms. Medications to treat severe constipation can be costly and can come with additional side effects. The fibre supplement that this study is investigating could be a natural alternative to help this constipated population.
Over a 2 month period, successful participants will take the food supplement or placebo product (non-active version of the fibre product, used as a control) daily for 6 weeks, track their bowel movements daily with an e-diary app, and visit Atlantia's clinic in Blackpool 3 times.
Each participant will receive €450 upon completion of the study in return for their time and any expenses.